Aimee Jackson

571 total citations
14 papers, 85 citations indexed

About

Aimee Jackson is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Aimee Jackson has authored 14 papers receiving a total of 85 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 4 papers in Genetics and 4 papers in Immunology. Recurrent topics in Aimee Jackson's work include Acute Myeloid Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). Aimee Jackson is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). Aimee Jackson collaborates with scholars based in United Kingdom, Australia and Denmark. Aimee Jackson's co-authors include Charlotte Gaskell, Sonia Fox, Neil Steven, Jennifer Pascoe, Lucinda Billingham, Claire Gaunt, Joyce Thompson, Charles Craddock, Rebecca H. Boucher and Toby A. Eyre and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Aimee Jackson

12 papers receiving 84 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aimee Jackson United Kingdom	5	41	31	26	22	17	14	85
Rathana Kim France	5	29 0.7×	17 0.5×	18 0.7×	8 0.4×	22 1.3×	11	73
Sergey Voloshin Russia	5	43 1.0×	27 0.9×	18 0.7×	25 1.1×	27 1.6×	50	87
Grzegorz Charliński Poland	8	70 1.7×	21 0.7×	31 1.2×	56 2.5×	62 3.6×	23	132
Giuseppe Sapienza Italy	5	43 1.0×	23 0.7×	6 0.2×	13 0.6×	23 1.4×	14	73
A. M. Vannucchi Italy	4	61 1.5×	33 1.1×	4 0.2×	21 1.0×	12 0.7×	14	81
Brian Ichihara United States	3	26 0.6×	9 0.3×	8 0.3×	20 0.9×	24 1.4×	3	87
Carla Araujo France	5	32 0.8×	12 0.4×	11 0.4×	27 1.2×	36 2.1×	8	58
Leo Ruhnke Germany	5	29 0.7×	14 0.5×	6 0.2×	27 1.2×	26 1.5×	13	79
Yuka Iijima‐Yamashita Japan	5	23 0.6×	6 0.2×	24 0.9×	22 1.0×	15 0.9×	10	58
Yervand Hakobyan Armenia	4	16 0.4×	32 1.0×	5 0.2×	10 0.5×	12 0.7×	13	66

Countries citing papers authored by Aimee Jackson

Since Specialization

Citations

This map shows the geographic impact of Aimee Jackson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimee Jackson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimee Jackson more than expected).

Fields of papers citing papers by Aimee Jackson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimee Jackson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimee Jackson. The network helps show where Aimee Jackson may publish in the future.

Co-authorship network of co-authors of Aimee Jackson

This figure shows the co-authorship network connecting the top 25 collaborators of Aimee Jackson. A scholar is included among the top collaborators of Aimee Jackson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimee Jackson. Aimee Jackson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

McIlroy, Graham, Charlotte Gaskell, Aimee Jackson, et al.. (2025). Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial. BMC Cancer. 25(1). 56–56. 1 indexed citations

McIlroy, Graham, Siân Lax, Charlotte Gaskell, et al.. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer. 24(1). 370–370. 1 indexed citations

Loke, Justin, Aimee Jackson, Shamyla Siddique, et al.. (2023). Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Advances. 7(14). 3666–3676. 21 indexed citations

Marks, David I., Anna Castleton, Eduardo Olavarría, et al.. (2023). ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission. BMJ Open. 13(6). e067790–e067790.

Dillon, Richard, Aimee Jackson, Sonia Fox, et al.. (2022). Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer. 22(1). 1174–1174. 2 indexed citations

Sternberg, Alexander, Rebecca H. Boucher, Manoj Raghavan, et al.. (2022). Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study). British Journal of Haematology. 199(2). 222–229. 2 indexed citations

Metzner, Marlen, Batchimeg Usukhbayar, Aimee Jackson, et al.. (2022). Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy. SHILAP Revista de lepidopterología. 3(3). 794–803. 2 indexed citations

Loke, Justin, Marlen Metzner, Rebecca H. Boucher, et al.. (2021). Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy. British Journal of Haematology. 196(2). 368–373. 3 indexed citations

Malladi, Ram, Ikhlaaq Ahmed, Graham McIlroy, et al.. (2021). Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial. Bone Marrow Transplantation. 56(12). 2948–2955.

10.

Pascoe, Jennifer, Aimee Jackson, Charlotte Gaskell, et al.. (2021). Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH). BMC Cancer. 21(1). 800–800. 18 indexed citations

11.

Drummond, Mark W., Charlotte Gaskell, Claire Harrison, et al.. (2020). Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]. Blood. 136(Supplement 1). 2–3. 10 indexed citations

12.

Ahearne, Matthew J., Charlotte Gaskell, Aimee Jackson, et al.. (2020). AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL). Blood. 136(Supplement 1). 18–19. 4 indexed citations

13.

Appleby, Niamh, Toby A. Eyre, Maité Cabes, et al.. (2019). The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 19(1). 471–471. 19 indexed citations

14.

Craddock, Charles, Aimee Jackson, Ram Malladi, et al.. (2019). The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial. Blood. 134(Supplement_1). 2031–2031. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact